Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mazzaferro, S.
Right arrow Articles by Carboni, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mazzaferro, S.
Right arrow Articles by Carboni, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2000) 15: 877-882
© 2000 European Renal Association-European Dialysis and Transplant Association


Brief Reports

Changes in bone turnover after parathyroidectomy in dialysis patients: role of calcitriol administration

Sandro Mazzaferro1,, Silvana Chicca1, Marzia Pasquali1, Francesco Zaraca2, Paola Ballanti3, Franco Taggi4, Giorgio Coen1, Giulio Alberto Cinotti1 and Manlio Carboni2

1 Department of Clinical Science, 2 2nd Surgical Clinic, 3 Department of Experimental Medicine and Pathology, University ‘La Sapienza’ and 4 Istituto Superiore di Sanità, Rome, Italy

Background. Available data on changes in serum levels of bone markers after parathyroidectomy (PTx) in dialysis patients are not uniform. Changes are thought to be due to either a reduction in PTH activity per se or to a direct effect of vitamin D therapy on bone cells. We aimed to verify whether treatment with vitamin D modifies serum levels of markers of bone synthesis (alkaline phosphatase (AP), osteocalcin (BGP), procollagen type I C-terminal peptide (PICP)) and resorption (collagen type I C-terminal peptide (ICTP)) within a period of 15 days in haemodialysis patients with severe secondary hyperparathyroidism following PTx.

Methods. We randomized two groups (A, treatment and B, placebo, 10 patients each) with comparable basal PTH values and measured bone markers 3, 7 and 15 days after surgery. All patients were treated with calcium supplements (i.v. and p.o.), and group A also received calcitriol (2.4±1.0 µg/day, p.o.).

Results. In both groups, PTx induced significant changes in all the markers evaluated, except for BGP in group B. Compared to basal values, ICTP decreased from 481±152 ng/ml in group A and 277±126 ng/ml in group B to 267±94 and 185±71 ng/ml (M±SD) respectively, and PICP increased from 307±139 ng/ml in group A and 309±200 ng/ml in group B to 1129±725 and 1231±1267 ng/ml (M±SD) respectively, within 3 days of surgery. AP values increased after 15 days from 1115±734 mU/ml in group A and 1419±1225 mU/ml in group B to 1917±1225 and 1867±1295 mU/ml (M±SD) respectively. On the contrary, mean values of BGP were never different from basal levels after PTx in either group. In the two groups, the pattern of changes of all the bone markers after PTx was almost identical. Group A patients predictably required lower doses of oral calcium supplements to correct hypocalcaemia (16.9±5.7 vs 22.1±5.0 g/10 days; M±SD, P<0.04).

Conclusions. The opposite behaviour of serum PICP and ICTP after PTx, in both the treated and untreated groups suggests that quantitative uncoupling between bone synthesis and resorption is responsible for hypocalcaemia. This phenomenon, as reflected by the evaluated bone markers, is unaffected by calcitriol. Based on our data we conclude that immediately after parathyroid surgery, vitamin D therapy does not influence bone cell activity, but improves hypocalcaemia mainly through its known effect on intestinal calcium absorption.

Keywords: alkaline phosphatase; bone markers; calcitriol, effects of; collagen type I C-terminal peptide (ICTP); parathyroidectomy; secondary hyperparathyroidism

Correspondence and offprint requests to: Dr Sandro Mazzaferro, Department of Clinical Science, c/o Policlinico Umberto I, 2 Clinica Medica, Viale del Policlinico, 151, I-00161 Rome, Italy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.